Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
MediWound Ltd., an Israeli biopharmaceutical company established in 2000 and based in Yavne, focuses on the innovation, production, and sale of advanced biological treatments for the healing and regrowth of damaged tissues. The company's key commercialized product is NexoBrid, a biological drug distributed to specialized burn centers and hospital burn units. NexoBrid is specifically formulated for the enzymatic debridement of eschar—dead or compromised tissue—in adults suffering from severe thermal burns, encompassing deep partial-thickness and full-thickness injuries. Furthermore, MediWound's development pipeline includes EscharEx, which has successfully concluded Phase II clinical trials for addressing chronic and other intractable wounds. Another investigational therapy, MW005, is currently undergoing Phase I/II clinical studies for the treatment of low-risk basal cell carcinoma.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of MDWD is 30 and suggests 114% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas